Colossal Biosciences

Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics.

Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth.

Colossal Biosciences was founded in 2021 by Ben Lamm and George Church. The company is headquartered in Dallas, Texas.


Colossal is the first to apply CRISPR technology for the purposes of species de-extinction. Colossal announced plans to de-extinct two essential species: the Woolly Mammoth and the Tasmanian tiger.


Colossal’s use of various gene editing technologies will make waves across sectors – in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development.


Colossal has also announced the launch of its Avian Genomics Group, which will pursue the de-extinction of the iconic Dodo, a bird species that was wiped out of its native ecosystem.


Colossal is backed by United States Innovative Technology Fund (USIT), Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, Jazz Ventures, Thomas Tull, At One Ventures, and others. The company raised $150M in Series B round on Jan 31, 2023. This brings Colossal's total funding to $225M to date. The latest round mints Colossal a unicorn with a valuation of over $1B post-money.



  • Year founded: 2021
  • Funding Info: $225M over 4 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: Valued at over $1B as of Jan 31, 2023
  • City/Town: Dallas
  • State: Texas
  • Country: United States
Related businesses